Clinical Trial

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2017-08-28; most recent amendment 2025-08-07.
Status change: Not Yet Recruiting → Recruiting 2019-03-11
Trial Details
NCT Number NCT03266653
Lead Sponsor New York Medical College
Collaborators: Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Indiana University, Washington University School of Medicine, University of California, Los Angeles, University of California, San Francisco
Conditions Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Enrollment 20 participants
Start Date 2020-07-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-08